Delivery of thymoquinone through hyaluronic acid-decorated mixed Pluronic® nanoparticles to attenuate angiogenesis and metastasis of triple-negative breast cancer

Bhattacharya, Saurav; Ghosh, Avijit; Maiti, Swatilekha; Ahir, Manisha; Debnath, Gouranga H.; Gupta, P. C. Sen; Bhattacharjee, Mousumi; Ghosh, Swatilekha; Chattopadhyay, Sreya; Mukherjee, Prasun; Adhikary, Arghya

doi:10.1016/j.jconrel.2020.03.033

Cited by 63 publications

(26 citation statements)

References 54 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The PEG and PCL, in the ball-milled NPs, decrease non-specific binding to the cell membrane and allow prolonged circulations. Hyaluronic acid (HA)-decorated Pluronic ® NPs of TQ accumulated in TNBC cells through selective binding with overexpressed CD44 receptor of cancer cells [ 194 ]. Pluronic-enhanced TQ encapsulation and HA facilitate CD44 targeting and make it have prolonged circulation, which reduced the dose for cell migration by modulating both miR-361/Rac1 and RhoA/actin stress fibers and the miR-361/VEGF-A mechanism that attenuate angiogenesis and metastasis of TNBC cells.…”

Section: Neoplasm and Its Pathogenesismentioning

confidence: 99%

Recent Findings on Thymoquinone and Its Applications as a Nanocarrier for the Treatment of Cancer and Rheumatoid Arthritis

et al. 2021

View full text Add to dashboard Cite

Cancer causes a considerable amount of mortality in the world, while arthritis is an immunological dysregulation with multifactorial pathogenesis including genetic and environmental defects. Both conditions have inflammation as a part of their pathogenesis. Resistance to anticancer and disease-modifying antirheumatic drugs (DMARDs) happens frequently through the generation of energy-dependent transporters, which lead to the expulsion of cellular drug contents. Thymoquinone (TQ) is a bioactive molecule with anticancer as well as anti-inflammatory activities via the downregulation of several chemokines and cytokines. Nevertheless, the pharmacological importance and therapeutic feasibility of thymoquinone are underutilized due to intrinsic pharmacokinetics, including short half-life, inadequate biological stability, poor aqueous solubility, and low bioavailability. Owing to these pharmacokinetic limitations of TQ, nanoformulations have gained remarkable attention in recent years. Therefore, this compilation intends to critically analyze recent advancements in rheumatoid arthritis and cancer delivery of TQ. This literature search revealed that nanocarriers exhibit potential results in achieving targetability, maximizing drug internalization, as well as enhancing the anti-inflammatory and anticancer efficacy of TQ. Additionally, TQ-NPs (thymoquinone nanoparticles) as a therapeutic payload modulated autophagy as well as enhanced the potential of other drugs when given in combination. Moreover, nanoformulations improved pharmacokinetics, drug deposition, using EPR (enhanced permeability and retention) and receptor-mediated delivery, and enhanced anti-inflammatory and anticancer properties. TQ’s potential to reduce metal toxicity, its clinical trials and patents have also been discussed.

show abstract

Section: Neoplasm and Its Pathogenesismentioning

confidence: 99%

Recent Findings on Thymoquinone and Its Applications as a Nanocarrier for the Treatment of Cancer and Rheumatoid Arthritis

et al. 2021

View full text Add to dashboard Cite

show abstract

“…TQ has been shown the ability to regulate certain miRNAs in different tissue cells or disease models. Bashir AO et al proved that TQ could potentiate the expression of miR-375 and miR-16 in hepatocellular carcinoma [32]; and Bhattacharya S et al proved that TQ administration through certain novel nanoparticles could suppress triple-negative breast cancer through modulating the expression level of miR-361 [33]. Accordingly, in this research, we also exploited the underlying mechanism of TQ inhibits the bladder carcinoma malignancy via regulating miRNAs.…”

Section: Introductionmentioning

confidence: 81%

Thymoquinone Suppresses the Proliferation, Migration and Invasiveness through Regulating ROS, Autophagic Flux and miR-877-5p in Human Bladder Carcinoma Cells

Zhou¹,

Wang²,

Wu³

et al. 2021

Int. J. Biol. Sci.

View full text Add to dashboard Cite

Bladder carcinoma is among the top 10 most frequently diagnosed cancer types in the world. As a phytochemical active metabolic, thymoquinone (TQ) is extracted from seeds of Nigella sativa, possessing various biological properties in a wide range of diseases. Moreover, the outstanding anti-cancer effect of TQ is attracting increasing attentions. In certain circumstances, moderate autophagy is regarded to facilitate the adaptation of malignant cells to different stressors. Conversely, closely linked with the mitochondrial membrane potential (MMP) loss, the upregulation of intracellular reactive oxygen species (ROS) is reported to activate the cell apoptosis in many cancer types. Furthermore, the vital effects of microRNAs in the pathological processes of cancer cells have also been confirmed by previous studies. The present research confirms that TQ restrains the viability, proliferation, migration and invasion through activating caspase-dependent apoptosis in bladder carcinoma cells, which is mediated by TQ induced ROS increase in bladder carcinoma cells. Furthermore, TQ is proved to block the fusion of autophagosomes and lysosomes, causing the accumulation of autophagosomes and subsequent cell apoptosis. In addition, TQ is also found to initiate the miR-877-5p/PD-L1 axis, which suppresses the epithelial mesenchymal transition (EMT) and invasion of bladder carcinoma cells. Taken together, TQ induces the apoptosis through upregulating ROS level and impairing autophagic flux, and inhibiting the EMT and cell invasion via activating the miR-877-5p/PD-L1 axis in bladder carcinoma cells.

show abstract

“…pH-sensitive ROZ-loaded mixed micelles were prepared by thin-film dispersion method. 28 In short, 17 mg of HA-DAS, 3 mg of TPGS, 2 mg of ROZ were mixed uniformly with 10 mL H 2 O/methanol mixed solution (v/v, 1:1) by ultrasonic. Hereafter the solvent was removed with a rotary evaporator to obtain a drug film which was dissolved with PBS (pH 7.4, 0.01 M).…”

Section: Preparation Of Ph-sensitive Roz-loaded Mixed Micellesmentioning

confidence: 99%

A Combined Self-Assembled Drug Delivery for Effective Anti-Breast Cancer Therapy

Wang¹,

Zhang²,

Zeng³

et al. 2021

IJN

View full text Add to dashboard Cite

The metastasis of breast cancer is an important cause of tumor recurrence. This study highlights that tyrosine kinase inhibitors dasatinib (DAS) and rosiglitazone (ROZ) inhibit tumor growth and reduce the occurrence of tumor cell metastasis. Due to the poor water solubility, short half-time in the body of DAS and ROZ, which increases the difficulty of tumor treatment, as well as the demand for nano-drug delivery systems for organ-specific therapies. Methods: Hyaluronic acid (HA) and DAS are bonded by a pH-sensitive ester bond to form an HA-DAS polymer. Then, ROZ was added as the core, D-A-tocopherol polydiethylene glycol isosuccinate (TPGS) and HA-DAS were used as carriers to form HA-DAS and TPGS mixed micelle system loaded with ROZ (THDR-NPs). The size and structure of THDR-NPs were characterized, the drug release, stability and biosafety of THDR-NPs were studied. In vitro, the cytotoxicity, targeting effect and tumor metastasis inhibition of THDR-NPs were evaluated in human breast cancer cell lines. In addition, the selective potency of designed THDR-NPs in depleting was further verified in vivo in the tumor-bearing nude mice model. Results: The designed THDR-NPs have a particle size of less than 100 nm, good stability, biological safety and sustained release, and showed strong therapeutic effects on breast cancer models in vitro and in vivo. Moreover, it has been proved that THDR-NPs have the ability to inhibit tumor metastasis. Conclusion: DAS and ROZ were designed into micelles, the efficacy of THDR-NPs was higher than that of free drugs. These results indicate that nanoparticles have a good application prospect in the treatment of tumor metastasis.

show abstract

Delivery of thymoquinone through hyaluronic acid-decorated mixed Pluronic® nanoparticles to attenuate angiogenesis and metastasis of triple-negative breast cancer

Cited by 63 publications

References 54 publications

Recent Findings on Thymoquinone and Its Applications as a Nanocarrier for the Treatment of Cancer and Rheumatoid Arthritis

Recent Findings on Thymoquinone and Its Applications as a Nanocarrier for the Treatment of Cancer and Rheumatoid Arthritis

Thymoquinone Suppresses the Proliferation, Migration and Invasiveness through Regulating ROS, Autophagic Flux and miR-877-5p in Human Bladder Carcinoma Cells

A Combined Self-Assembled Drug Delivery for Effective Anti-Breast Cancer Therapy

Contact Info

Product

Resources

About